PAVmed (NASDAQ:PAVM – Get Free Report) is one of 511 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare PAVmed to similar businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.
Profitability
This table compares PAVmed and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PAVmed | -10,794.64% | -126.43% | -25.49% |
| PAVmed Competitors | -278.16% | -150.10% | -21.89% |
Analyst Ratings
This is a summary of current ratings and target prices for PAVmed and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PAVmed | 1 | 1 | 1 | 0 | 2.00 |
| PAVmed Competitors | 4266 | 10511 | 18264 | 826 | 2.46 |
PAVmed currently has a consensus price target of $56.00, indicating a potential upside of 3,283.69%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 18.68%. Given PAVmed’s higher probable upside, equities analysts plainly believe PAVmed is more favorable than its peers.
Earnings & Valuation
This table compares PAVmed and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| PAVmed | $112,000.00 | $400,000.00 | -0.10 |
| PAVmed Competitors | $1.89 billion | $138.79 million | 11.23 |
PAVmed’s peers have higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
19.9% of PAVmed shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
PAVmed has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, PAVmed’s peers have a beta of 2.56, indicating that their average share price is 156% more volatile than the S&P 500.
Summary
PAVmed peers beat PAVmed on 11 of the 13 factors compared.
About PAVmed
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Receive News & Ratings for PAVmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAVmed and related companies with MarketBeat.com's FREE daily email newsletter.
